MarketPulse

Forendo acquisition

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Kdventures Ab

Organon Discontinues Second Forendos Drug Candidate, KDventures Faces Total Loss

Organon discontinues second Forendo drug candidate for PCOS, eliminating all programs from 2021 acquisition. KDventures writes off remaining contingent consideration entirely.
OGNpharmaceutical developmentdrug development discontinuation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Organon Scraps PCOS Drug Candidate, Dealing Second Blow to KDventures' Forendo Bet

Organon discontinues PCOS drug candidate, marking total failure of KDventures' 2021 Forendo acquisition. Contingent consideration fully written off after second portfolio termination.
OGNdrug development discontinuationForendo acquisition